Giant Biogene Holding Future Growth
Future criteria checks 6/6
Giant Biogene Holding is forecast to grow earnings and revenue by 23.4% and 20.9% per annum respectively. EPS is expected to grow by 22.6% per annum. Return on equity is forecast to be 34.1% in 3 years.
Key information
23.4%
Earnings growth rate
22.6%
EPS growth rate
Personal Products earnings growth | 18.1% |
Revenue growth rate | 20.9% |
Future return on equity | 34.1% |
Analyst coverage | Good |
Last updated | 18 Dec 2024 |
Recent future growth updates
Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%
Aug 21Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
Mar 27Recent updates
Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 20Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%
Aug 21Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?
Aug 09Giant Biogene Holding Co., Ltd.'s (HKG:2367) Popularity With Investors Is Clear
Jul 01Is Giant Biogene Holding Co., Ltd. (HKG:2367) Trading At A 32% Discount?
Apr 17Investors Interested In Giant Biogene Holding Co., Ltd.'s (HKG:2367) Earnings
Mar 28Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
Mar 27Do Giant Biogene Holding's (HKG:2367) Earnings Warrant Your Attention?
Dec 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 8,507 | 3,133 | 2,563 | 3,148 | 20 |
12/31/2025 | 6,694 | 2,521 | 2,086 | 2,507 | 21 |
12/31/2024 | 5,105 | 1,973 | 1,463 | 2,064 | 21 |
6/30/2024 | 4,459 | 1,768 | 1,670 | 1,877 | N/A |
3/31/2024 | 3,992 | 1,610 | 1,545 | 1,762 | N/A |
12/31/2023 | 3,524 | 1,452 | 1,419 | 1,647 | N/A |
9/30/2023 | 3,255 | 1,252 | 1,218 | 1,480 | N/A |
6/30/2023 | 2,985 | 1,052 | 1,016 | 1,313 | N/A |
3/31/2023 | 2,675 | 874 | 897 | 1,122 | N/A |
12/31/2022 | 2,364 | 696 | 778 | 932 | N/A |
12/31/2021 | 1,552 | 809 | 617 | 692 | N/A |
12/31/2020 | 1,190 | 826 | 758 | 834 | N/A |
12/31/2019 | 957 | 552 | 571 | 656 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2367's forecast earnings growth (23.4% per year) is above the savings rate (2.3%).
Earnings vs Market: 2367's earnings (23.4% per year) are forecast to grow faster than the Hong Kong market (11.6% per year).
High Growth Earnings: 2367's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2367's revenue (20.9% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 2367's revenue (20.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2367's Return on Equity is forecast to be high in 3 years time (34.1%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/18 16:50 |
End of Day Share Price | 2024/12/18 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Giant Biogene Holding Co., Ltd. is covered by 27 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Junhao Fan | China International Capital Corporation Limited |
Zhuonan Xu | China International Capital Corporation Limited |
Yishan Li | China Merchants Securities (HK) Co., Ltd |